ACADIA Pharmaceuticals (ACAD) Stock Statistics & Valuation Metrics
Total Valuation
ACADIA Pharmaceuticals has a market cap or net worth of MXN 66.67B. The enterprise value is MXN 3.49B.
- Market Cap
- MXN 66.67B
- Enterprise Value
- MXN 3.49B
Share Statistics
ACADIA Pharmaceuticals has 172,305,510 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 172,305,510
- Owned by Insiders
- 23.14%
- Owned by Institutions
- 39.48%
Financial Efficiency
ACADIA Pharmaceuticals’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is 8.07%.
- Return on Equity (ROE)
- 0.32
- Return on Assets (ROA)
- 0.25
- Return on Invested Capital (ROIC)
- 8.07%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 1.34M
- Profits Per Employee
- 490.59K
- Employee Count
- 797
- Asset Turnover
- 0.69
- Inventory Turnover
- 2.57
Valuation Ratios
The current PE Ratio of ACADIA Pharmaceuticals is 9.15. ACADIA Pharmaceuticals’s PEG ratio is 0.13.
- PE Ratio
- 9.15
- PS Ratio
- 3.12
- PB Ratio
- 2.70
- Price to FCF
- 20.34
- Price to Operating Cash Flow
- 18.18
- PEG Ratio
- 0.13
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 1.07B and earned 391.00M in profits. Earnings per share was 2.32.
- Revenue
- 1.07B
- Gross Profit
- 982.51M
- Operating Income
- 104.81M
- Pretax Income
- 138.90M
- Net Income
- 391.00M
- EBITDA
- 150.66M
- Earnings Per Share (EPS)
- 2.32
Cash Flow
In the last 12 months, operating cash flow was 194.30M and capital expenditures -19.91M, giving a free cash flow of 174.39M billion.
- Operating Cash Flow
- 194.30M
- Free Cash Flow
- 174.39M
- Free Cash Flow per Share
- 1.02
Dividends & Yields
ACADIA Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.92%
- Earnings Yield
- 10.77%
Stock Price Statistics
- Beta
- -0.12
- 52-Week Price Change
- -11.59%
- 50-Day Moving Average
- 425.97
- 200-Day Moving Average
- 408.48
- Relative Strength Index (RSI)
- 59.02
- Average Volume (3m)
- 132
Important Dates
ACADIA Pharmaceuticals upcoming earnings date is Nov 04, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 04, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- ―
Financial Position
ACADIA Pharmaceuticals as a current ratio of 3.83, with Debt / Equity ratio of 4.25%
- Current Ratio
- 3.83
- Quick Ratio
- 3.71
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.83
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, ACADIA Pharmaceuticals has paid -252.10M in taxes.
- Income Tax
- -252.10M
- Effective Tax Rate
- -1.81
Enterprise Valuation
ACADIA Pharmaceuticals EV to EBITDA ratio is 27.87, with an EV/FCF ratio of 18.56.
- EV to Sales
- 2.84
- EV to EBITDA
- 27.87
- EV to Free Cash Flow
- 18.56
- EV to Operating Cash Flow
- 16.66
Balance Sheet
ACADIA Pharmaceuticals has MXN 956.47M in cash and marketable securities with MXN 73.85M in debt, giving a net cash position of MXN 882.62M billion.
- Cash & Marketable Securities
- MXN 956.47M
- Total Debt
- MXN 73.85M
- Net Cash
- MXN 882.62M
- Net Cash Per Share
- MXN 5.12
- Tangible Book Value Per Share
- MXN 7.01
Margins
Gross margin is 91.13%, with operating margin of 7.59%, and net profit margin of 33.42%.
- Gross Margin
- 91.13%
- Operating Margin
- 7.59%
- Pretax Margin
- 10.66%
- Net Profit Margin
- 33.42%
- EBITDA Margin
- 10.20%
- EBIT Margin
- 9.14%
Analyst Forecast
The average price target for ACADIA Pharmaceuticals is MXN 587.78, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- MXN 587.78
- Price Target Upside
- 51.10% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 15
- Revenue Growth Forecast
- 1.71%
- EPS Growth Forecast
- 54.89%
Scores
- Smart Score
- 5
- AI Score
- ―
